title: Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.
abstract: The significance of the polymerase chain reaction (PCR) in the detection of minimal residual disease in Philadelphia chromosome (Ph')-positive chronic myelogenous leukemia (CML) following interferon therapy was investigated. Forty remission blood samples obtained at various remission time points from 29 patients in complete cytogenetic remission were analyzed. All 40 samples showed minimal residual Ph'-positive cells by PCR: 22 in remission for less than 12 months, 12 in remission for 12 to 24 months, four in remission for 25 to 60 months, and two in remission for more than 60 months. Of these 29 patients, seven relapsed at 4, 6, 9, 14, 17, 19, and 50 months after their first PCR-positivity during remission. One developed extramedullary myelopoiesis at 49 months after PCR-positivity. The remaining 21 patients remained in complete hematologic and cytogenetic remission with median follow-up of 13 months (range, 4 to 36 months) after PCR analysis. These findings indicate that PCR-positivity is not associated with immediate disease recurrence. Long-term follow-up is essential to determine the relevance of PCR-positivity, since late recurrence is observed in our study.
authors.affiliation: Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
authors.forename: M S
authors.initials: MS
authors.lastname: Lee
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: E J
authors.initials: EJ
authors.lastname: Freireich
authors.forename: A
authors.initials: A
authors.lastname: Deisseroth
authors.forename: J M
authors.initials: JM
authors.lastname: Trujillo
authors.forename: S A
authors.initials: SA
authors.lastname: Stass
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001853:Bone Marrow / Q000473:pathology; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016133:Polymerase Chain Reaction / Q000379:methods*; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis*; D013997:Time Factors; D014158:Transcription, Genetic
chemical_list: D014408:Biomarkers, Tumor; D016898:Interferon-alpha; D012333:RNA, Messenger; D007371:Interferon-gamma; D016044:Fusion Proteins, bcr-abl